Swissmedic Approves Eisai's Inovelon® (rufinamide) Oral Suspension Formulation For Seizures Associated With Lennox-Gastaut Syndrome In Switzerland
July 13, 2012
Eisai Europe Limited have announced the Swissmedic approval of Inovelon® (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients over the age of 4 years in Switzerland...
Return to Epilepsy News
